epirubicin + carboplatin + docetaxel

Epirubicin + carboplatin + docetaxel is a combination chemotherapy regimen composed of three cytotoxic agents frequently used in the treatment of various cancers, particularly breast cancer. - **Epirubicin** is an anthracycline antibiotic that intercalates DNA strands and inhibits topoisomerase II, leading to DNA damage and apoptosis in rapidly dividing cells. - **Carboplatin** is a platinum-based compound that forms DNA crosslinks, interfering with DNA replication and transcription, ultimately causing cell death. - **Docetaxel** is a taxane that stabilizes microtubules and prevents their depolymerization during cell division, resulting in mitotic arrest and apoptosis. This combination has been investigated as an intensive weekly or neoadjuvant regimen for triple-negative breast cancer (TNBC) and metastatic breast cancer[1][4]. The rationale for combining these agents lies in their complementary mechanisms of action targeting different aspects of tumor cell proliferation.

Other names

epirubicin/carboplatin/docetaxelDECb